Tenecteplase in the treatment of acute ischemic stroke：a rapid health technology assessment
- VernacularTitle:替奈普酶治疗急性缺血性脑卒中的快速卫生技术评估
- Author:
Xiaomei DENG
1
,
2
;
Huiting LI
1
,
2
;
Peng MEN
3
,
4
;
Zhetao ZHANG
1
,
2
;
Jin ZHANG
1
,
2
;
Tianlu SHI
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of USTC （Anhui Provincial Hospital），Hefei 230036，China
2. Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy，Hefei 230001，China
3. Dept. of Pharmacy，Peking University Third Hospital，Beijing 100191，China
4. Institute for Drug Evaluation，Peking University Health Science Center，Beijing 100191，China
- Publication Type:Journal Article
- Keywords:
tenecteplase;
acute ischemic stroke;
rapid health technology assessment;
effectiveness;
safety;
cost-effectiveness
- From:
China Pharmacy
2024;35(20):2541-2547
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To assess the efficacy， safety and cost-effectiveness of tenecteplase in the treatment of acute ischemic stroke， and to provide a basis for clinical rational drug use and related decision-making. METHODS The related literature in the PubMed， the Cochrane Library， CNKI， Wanfang data and health technology assessment （HTA） databases were searched from the establishment of the database to June 30th， 2024. Systematic reviews/meta-analyses， pharmacoeconomic studies and HTA reports on tenecteplase in the treatment of acute ischemic stroke were collected. After data extraction and quality assessment， descriptive analysis of the included studies was carried out. RESULTS A total of 31 articles were included， involving 28 systematic reviews/ meta-analysis and 3 pharmacoeconomic studies. In terms of effectiveness， compared with alteplase， tenecteplase （0.25 mg/kg） could significantly increase the early neurological improvement； the 90 d excellent neurological recovery rate， 90 d good neurological recovery rate， and recanalization were not inferior to alteplase. For safety， compared with alteplase， tenecteplase did not increase the incidence of hemorrhage， symptomatic intracranial hemorrhage， 3-month mortality， or intracranial hemorrhage. In terms of cost-effectiveness， foreign research results showed that tenecteplase had economic advantages over alteplase. CONCLUSIONS Compared with alteplase， tenecteplase is effective and safe in the treatment of acute ischemic stroke， and it is cost-effective.
